Citi: Initiates 90-day catalyst observation period for INNOVENT BIO (01801) with a target price of HK$62.

Citibank released a research report stating that they have started a 90-day catalyst observation period for INNOVENT BIO (01801). The bank expects that with the drive of new products, the strong growth momentum of INNOVENT BIO will continue. Taletrectinib (ROS1)/Mazdutide/IBI311 (IGF-1R)/IBI112 (IL-23 p19) are expected to be approved in the second half of this year or next year. The target price is 62 Hong Kong dollars, with a rating of "buy/high risk".